North America RNA Therapeutics Market Research 2024-2029: Revolutionary Advancements in RNA Technology and Personalized Medicine Propel Growth
November 14, 2024 05:21 ET
|
Research and Markets
Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "North America RNA Therapeutics Market, By Country, Competition, Forecast & Opportunities, 2019-2029F" report has been added to ...
mRNA Therapeutics Industry Research 2024-2028 & Long-term Forecast to 2033: Emerging Self-Amplifying mRNA Platforms, Scalability and Flexibility Expected to Revolutionize Vaccine Development
October 15, 2024 04:03 ET
|
Research and Markets
Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "mRNA Therapeutics Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The mRNA therapeutics market size has grown steadily...
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
September 24, 2024 08:01 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within core activities in RNA delivery, supported by move into new...
Global Exosome Market Size, Forecast, Trials and Trends 2024: Exosome-Based Diagnostics and Therapeutics are Expanding, with 388 Clinical Trials Currently Underway
September 10, 2024 05:39 ET
|
Research and Markets
Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Global Exosome Market: Size, Forecast, Trials, and Trends, 2024" report has been added to ResearchAndMarkets.com's offering. Exosomes are...
SENISCA appoints Tim Edwards as Chair of the Board
September 10, 2024 02:00 ET
|
Senisca Ltd
Life-science leader with 30 years of experience to guide SENISCA towards becoming a clinical stage novel senotherapeutics company Exeter, UK — 10 September 2024: SENISCA SENISCA, a biotechnology...
RNA Therapeutics Market Size is expected to reach US$ 948 Million by 2031, Report by CoherentMI
September 09, 2024 11:10 ET
|
CMI
Burlingame, Sept. 09, 2024 (GLOBE NEWSWIRE) -- CoherentMI published a report, titled, RNA Therapeutics Market is estimated to value at US$ 2.5 Million in the year 2024 and is anticipated to reach...
RIGImmune Announces Multiple Oral Presentations for Intranasal RIG-101 at European Respiratory Society Congress 2024
September 09, 2024 07:55 ET
|
RIGImmune
Pre-clinical studies for intranasal RIG-101, a first in class RIG-I agonist, demonstrate potent local innate immune stimulation and pan-viral activity against human rhinovirus, influenza and RSV...
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
August 12, 2024 09:02 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Treatment with ZbtbB46 mRNA nanoparticles based on Altamira’s SemaPhore™ delivery technology results in significant reduction in...
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
July 30, 2024 09:05 ET
|
ADARx Pharmaceuticals
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
U.S. mRNA Synthesis Raw Materials (Capping Agents, Nucleotides, Plasmid DNA) Market Research 2024-2030: Growing Academic & Industrial Interest in MRNA Technology to Bolster Growth
July 10, 2024 10:28 ET
|
Research and Markets
Dublin, July 10, 2024 (GLOBE NEWSWIRE) -- The "U.S. mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report, Type (Capping Agents, Nucleotides, Plasmid DNA), Application...